Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
(2017) In Autoimmunity Reviews 16(4). p.343-351- Abstract
Objectives Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus (SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic outcomes, and sought to identify predictors of treatment response in three Swedish real-life settings. Methods Fifty-eight patients were enrolled at initiation of belimumab and followed longitudinally for up to 53 months. Surveillance outcomes included the SLE Disease Activity Index 2000 (SLEDAI-2K), 100 mm Visual Analogue Scales for Physician's Global Assessment (PGA), fatigue, pain and general health, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Assessment of treatment response included the SLE... (More)
Objectives Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus (SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic outcomes, and sought to identify predictors of treatment response in three Swedish real-life settings. Methods Fifty-eight patients were enrolled at initiation of belimumab and followed longitudinally for up to 53 months. Surveillance outcomes included the SLE Disease Activity Index 2000 (SLEDAI-2K), 100 mm Visual Analogue Scales for Physician's Global Assessment (PGA), fatigue, pain and general health, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Assessment of treatment response included the SLE responder index (SRI). B lymphocyte stimulator (BLyS) levels were determined using ELISA. Results SLEDAI-2K (median baseline score: 8.0; IQR: 4.0–13.8), PGA and corticosteroid use decreased during therapy, and patients reported improvements on fatigue, pain, and general health (p < 0.0001 for all). SDI scores remained stable (p = 0.08). Patients with baseline SDI scores > 1 showed decreased probability and prolonged time to attain SRI response (HR: 0.449; 95% CI: 0.208–0.967), as did current smokers compared with non-smokers (HR: 0.103; 95% CI: 0.025–0.427). In contrast, baseline BLyS levels ≥ 1.2 ng/mL predicted increased probability and shorter time to attain SRI response (HR: 2.566; 95% CI: 1.222–5.387). Conclusions Disease activity and corticosteroid usage decreased, patient-reported outcomes improved, and no significant organ damage was accrued during follow-up. Smoking and organ damage predicted reduced treatment efficacy. These findings might contribute to a better selection of patients who are likely to benefit from belimumab.
(Less)
- author
- organization
- publishing date
- 2017-04-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- BAFF, Belimumab, Biologics, BLyS, Systemic lupus erythematosus
- in
- Autoimmunity Reviews
- volume
- 16
- issue
- 4
- pages
- 9 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:28216072
- wos:000399266200003
- scopus:85016216057
- ISSN
- 1568-9972
- DOI
- 10.1016/j.autrev.2017.02.005
- language
- English
- LU publication?
- yes
- id
- 0bf2cadf-9bff-417a-a6a1-614ae8866c56
- date added to LUP
- 2017-04-26 14:43:07
- date last changed
- 2024-04-14 09:24:29
@article{0bf2cadf-9bff-417a-a6a1-614ae8866c56,
abstract = {{<p>Objectives Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus (SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic outcomes, and sought to identify predictors of treatment response in three Swedish real-life settings. Methods Fifty-eight patients were enrolled at initiation of belimumab and followed longitudinally for up to 53 months. Surveillance outcomes included the SLE Disease Activity Index 2000 (SLEDAI-2K), 100 mm Visual Analogue Scales for Physician's Global Assessment (PGA), fatigue, pain and general health, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Assessment of treatment response included the SLE responder index (SRI). B lymphocyte stimulator (BLyS) levels were determined using ELISA. Results SLEDAI-2K (median baseline score: 8.0; IQR: 4.0–13.8), PGA and corticosteroid use decreased during therapy, and patients reported improvements on fatigue, pain, and general health (p < 0.0001 for all). SDI scores remained stable (p = 0.08). Patients with baseline SDI scores > 1 showed decreased probability and prolonged time to attain SRI response (HR: 0.449; 95% CI: 0.208–0.967), as did current smokers compared with non-smokers (HR: 0.103; 95% CI: 0.025–0.427). In contrast, baseline BLyS levels ≥ 1.2 ng/mL predicted increased probability and shorter time to attain SRI response (HR: 2.566; 95% CI: 1.222–5.387). Conclusions Disease activity and corticosteroid usage decreased, patient-reported outcomes improved, and no significant organ damage was accrued during follow-up. Smoking and organ damage predicted reduced treatment efficacy. These findings might contribute to a better selection of patients who are likely to benefit from belimumab.</p>}},
author = {{Parodis, Ioannis and Sjöwall, Christopher and Jönsen, Andreas and Ramsköld, Daniel and Zickert, Agneta and Frodlund, Martina and Sohrabian, Azita and Arnaud, Laurent and Rönnelid, Johan and Malmström, Vivianne and Bengtsson, Anders A. and Gunnarsson, Iva}},
issn = {{1568-9972}},
keywords = {{BAFF; Belimumab; Biologics; BLyS; Systemic lupus erythematosus}},
language = {{eng}},
month = {{04}},
number = {{4}},
pages = {{343--351}},
publisher = {{Elsevier}},
series = {{Autoimmunity Reviews}},
title = {{Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus}},
url = {{http://dx.doi.org/10.1016/j.autrev.2017.02.005}},
doi = {{10.1016/j.autrev.2017.02.005}},
volume = {{16}},
year = {{2017}},
}